Almirall (FRA:E2Z) Change In Receivables : €0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Almirall Change In Receivables?

Almirall's change in receivables for the quarter that ended in Mar. 2024 was €0.0 Mil. It means Almirall's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Almirall's change in receivables for the fiscal year that ended in Dec. 2023 was €-3.1 Mil. It means Almirall's Accounts Receivable increased by €3.1 Mil from Dec. 2022 to Dec. 2023 .

Almirall's Accounts Receivable for the quarter that ended in Mar. 2024 was €147.1 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Almirall's Days Sales Outstanding for the three months ended in Mar. 2024 was 53.95.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Almirall's liquidation value for the three months ended in Mar. 2024 was €-326.8 Mil.

Almirall Change In Receivables Historical Data

The historical data trend for Almirall's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall Change In Receivables Chart

Almirall Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

80.66

105.98

-13.11

2.88

-3.15

Almirall Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Almirall Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Almirall (FRA:E2Z) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Almirall's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	147.1	/	248.8	*	91
=	53.95

2. In Ben Graham's calculation of liquidation value, Almirall's accounts receivable are only considered to be worth 75% of book value:

Almirall's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	314.3	-	831	+	0.75 * 147.1	+	0.5 * 159.2
=	-326.8

Almirall Change In Receivables Related Terms

Thank you for viewing the detailed overview of Almirall's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Almirall (FRA:E2Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (FRA:E2Z) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

LBTSF:USA 0O9B:UK ALM:Spain E2Z:Germany

Address

Ronda General Mitre 151, Barcelona, ESP, 08022

Website

http://www.almirall.es

Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Almirall (FRA:E2Z) Headlines

No Headlines